anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
COMBOGESIC IV (acetaminophen and ibuprofen) injection contains acetaminophen and ibuprofen, a nonsteroidal anti-inflammatory drug.

Acetaminophen chemical name is N-acetyl-p-aminophenol. Acetaminophen is a white, odorless, crystalline powder, possessing a slightly bitter taste. Acetaminophen is soluble in boiling water and 1N sodium hydroxide and is freely soluble in alcohol. Acetaminophen has a molecular weight of 151.16. The molecular formula is C8H9NO2 and the structural formula is:

Ibuprofen sodium dihydrate chemical name is 2-(4-isobutyl phenyl) propionic acid sodium salt dihydrate. Ibuprofen sodium dihydrate is a white powder. It has a molecular weight of 264.29. It is freely soluble in water. The molecular formula is C13H21NaO4 and the structural formula of ibuprofen sodium dihydrate is represented below:

COMBOGESIC IV injection is a sterile, clear, colorless, non-pyrogenic, isotonic solution, intended for intravenous infusion with a pH stability range of 6.3-7.3.

Each single-dose 100 mL vial contains 1,000 mg of acetaminophen and 300 mg of ibuprofen base (equivalent to 385 mg of ibuprofen sodium dihydrate), 25 mg of Cysteine hydrochloride monohydrate, 13 mg of Disodium phosphate dihydrate, 3,285 mg of Mannitol, Hydrochloric acid (for pH adjustment), Sodium hydroxide (for pH adjustment), Water for injection.
A Chinese medicinal capsule for treating pain in neck, shoulder, waist and leg is prepared from pure natural Chinese medicinal materials including radix Aconiti, radix Aconiti Kusnezoffii, rhizoma Ligustici Chuanxiong, rhizoma Atractylodis, radix Aconiti lateralis Preparata, fructus Chaenomelis, ramulus Cinnamomi, Achyranthis radix, rhizoma Zingiberis recens, and herba Alii Fistulosi. The Chinese herbal medicines of raw radix aconiti, raw radix aconiti agrestis, rhizoma ligustici wallichii, rhizoma atractylodis and radix aconiti lateralis preparata are respectively prepared into particles with the size of about half centimeter according to the dosage proportion; cutting rhizoma Zingiberis recens and herba Alii Fistulosi into small segments, mixing with the above materials, mashing, mixing with the above materials, placing into jar, burying underground, taking out after one month, and air drying; mixing fructus Chaenomelis, ramulus Cinnamomi, and Achyranthis radix with the above materials, pulverizing into fine powder, sterilizing, and making into capsule. The invention is used for treating neck, shoulder, waist and leg pains caused by various reasons, including cervical spondylosis, lumbar muscle strain, knee joint hyperosteogeny, rheumatoid arthritis and the like. Has the effects of relaxing muscles and tendons, activating collaterals, promoting blood circulation, and relieving pain. The capsule has the advantages of convenient and safe administration, small toxic and side effects, obvious curative effect and more than 95 percent of total effective rate. Is worthy of clinical popularization and application.
Laundry detergents useful for cold-water cleaning and boosted bargain detergents are disclosed. The detergents include a surfactant composition derived from a metathesis-derived C10-C17 monounsaturated acid, octadecene-1,18-dioic acid, or their ester derivatives. For fatty alkyl ester sulfonate-containing detergents, the composition is selected from C10 betaines, C12 or C16 amidoamines, C1 2 ethanolamine amides, C16 amidoamine sulfonates, C18 diamidoamine dioxides, quaternized C18 diamidoamine betaines, sulfonated C18 low-EO fatty ester alkoxylates, C18 amidoamine carboxylates, and amidoamine oxides and sulfobetaines derived from cross- metathesis of palm or soybean oil. The bargain detergents include a performance booster selected from C12 low-EO fatty ester alkoxylate sulfonates, C18 amidoamine oxide esters, C18 amidoamine oxide carboxylates, and amidoamine sulfobetaines made from self metathesized palm or soybean oil. Laundry detergents useful for cold-water cleaning and boosted bargain detergents are disclosed. The detergents include a surfactant composition derived from a metathesis-derived C10-C17 monounsaturated acid, octadecene-1,18-dioic acid, or their ester derivatives. For fatty alkyl ester sulfonate-containing detergents, the composition is selected from C10 betaines, C12 or C16 amidoamines, C1 2 ethanolamine amides, C16 amidoamine sulfonates, C18 diamidoamine dioxides, quaternized C18 diamidoamine betaines, sulfonated C18 low-EO fatty ester alkoxylates, C18 amidoamine carboxylates, and amidoamine oxides and sulfobetaines derived from cross- metathesis of palm or soybean oil. The bargain detergents include a performance booster selected from C12 low-EO fatty ester alkoxylate sulfonates, C18 amidoamine oxide esters, C18 amidoamine oxide carboxylates, and amidoamine sulfobetaines made from self metathesized palm or soybean oil. Cellulosic tissue sheets having temporary moisture barrier properties are prepared by applying a solution of reactive size in emollient at an elevated temperature to a previously formed tissue sheet.
Amiodarone, like other antiarrhythmics, can cause serious exacerbation of the presenting arrhythmia, a risk that may be enhanced by the presence of concomitant antiarrhythmics. Exacerbation has been reported in about 2 to 5% in most series, and has included new ventricular fibrillation, incessant ventricular tachycardia, increased resistance to cardioversion and polymorphic ventricular tachycardia associated with QTc prolongation (Torsade de Pointes [TdP]). In addition, amiodarone has caused symptomatic bradycardia or sinus arrest with suppression of escape foci in 2 to 4% of patients.

Fluoroquinolones, macrolide antibiotics, and azoles are known to cause QTc prolongation. There have been reports of QTc prolongation, with or without TdP, in patients taking amiodarone when fluoroquinolones, macrolide antibiotics, or azoles were administered concomitantly. (See "Drug Interactions, Other reported interactions with amiodarone".)

The need to co-administer amiodarone with any other drug known to prolong the QTc interval must be based on a careful assessment of the potential risks and benefits of doing so for each patient.

A careful assessment of the potential risks and benefits of administering Pacerone® Tablets must be made in patients with thyroid dysfunction due to the possibility of arrhythmia breakthrough or exacerbation of arrhythmia in these patients.
Forty patients were randomised, 18 patients had a laparoscopic appendectomy and 22 patients had a laparoscopic inspection only. The postoperative pain scores were significantly different favouring appendix removal (p \< 0.01). Relative risk calculations indicated a 2.4 fold (95% CI: 1.3 - 4.0) greater chance of improving or becoming pain free after laparoscopic appendectomy. The number needed to treat was 2.2 patients (95% CI: 1.5 - 6.5). There was no significant relation between postoperative pain scores and histopathology findings.

Conclusions Chronic or recurrent appendicitis is a realistic clinical entity that can be treated successfully by elective appendectomy leading to significant pain reduction in properly selected cases. Histopathology of the removed appendix does not contribute to the diagnosis.
Participants will receive a dosage of Metoprolol taking into consideration prior beta-blocker use and concomitant medications. Within the run-in period, the dosage will be increased to the maximum tolerable dose. Whether metoprolol sustained release will be dosed QD or BID, will be up to the investigator and patient preference. The maximum daily dose of metoprolol will not exceed 200 mg.
The HICON trial is a prospective, single-center, nonrandomized, explorative imaging study evaluating the value of PET (Positron emission tomography) as a predictor of histopathological response in metabolic non-responders Patients with resectable AEG (adenocarcinoma of the esophagogastric junction) type I and II, staged cT3/4 and/or cN+ and cM0 by endoscopic ultrasound, spiral CT or MRI and FDG-PET are eligible. Tumors must be potentially R0 resectable and must have a sufficient FDG-baseline uptake. Only metabolic non-responders, showing a \<35% decrease of SUV (standardized uptake value) two weeks after the start of neoadjuvant chemotherapy are eligible for the study and are taken to intensified taxane-based RCT (chemoradiotherapy (45 Gy) before surgery. 18FDG-PET scans will be performed before (=Baseline) and after 14 days of standard neoadjuvant therapy as well after the first cycle of Taxotere/Cisplatin chemotherapy (=PET1) and at the end of intensified radiochemotherapy (PET2). Tracer uptake will be assessed semiquantitatively using standardized uptake values (SUV). The percentage difference Delta SUV=100(SUVBaseline-SUVPET1)/ SUVBaseline will be calculated and assessed as an early predictor of histopathological response. In a secondary analysis, the association between the difference SUVPET1 - SUVPET2 and histopathological response will be evaluated..
Patients receive cytarabine IV over 3 hours every 12 hours on days 1-4 and idarubicin IV over 5-10 minutes on days 1-3. Patients undergo bone marrow aspirate and biopsy 7 days after completion of induction chemotherapy. Patients with \> 25% cellular biopsy or \> 10% abnormal cells on aspirate receive 4 more doses of cytarabine and 1 dose of idarubicin.
The present invention relates to the field of biomedicines, and specifically provides an anti-LAG-3 monoclonal antibody, and an antigen-binding fragment and an application thereof. The anti-LAG-3 monoclonal antibody comprises a heavy chain variable region and a light chain variable region. The monoclonal antibody or the antigen-binding fragment thereof is selected from any one of A-1, A-2, A-3, and A-4. The provided monoclonal antibody can specifically bind to LAG-3, has higher affinity, has good biological activity, and can be used for treating a plurality of cancers or immune diseases. The cancers comprise leukemia, lung cancer, gastric cancer, esophageal cancer, ovarian cancer, head and neck cancer, melanoma, renal cancer, breast cancer, colorectal cancer, liver cancer, pancreatic cancer, and bladder cancer. The immune diseases comprise psoriasis, Crohn's disease, rheumatoid arthritis, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, ulcerative colitis, and autoimmune hepatitis.
The present invention provides a curable composition allowing a cured product having high aesthetic quality, strength and durability along with having high surface lubricating property to be formed. The curable composition according to the present invention comprises: an inorganic powder and a polymerizable monomer. The inorganic powder contains a spherical crystallization control powder. The spherical crystallization control powder has a silicon dioxide content in the range of 97 to 100 mass %. An amorphous portion and a crystalline portion are mixed within the spherical crystallization control powder. A refractive index difference is not more than 0.05 between the spherical crystallization control powder and a cured product obtained by curing only constituents other than the spherical crystallization control powder.
1,272,640. Sustained and/or delayed release medicaments. K. G. ERIKSSON and A. MANGEN. 5 June, 1969 [19 June, 1968], No. 28575/69. Heading A5B. A sustained or delayed release medicament dosage is made by forming granules comprising the medicament and a substance (A) capable of delaying its dissolution in the gastrointestinal tract, dispersing the granules in a melt of a carrier substance (B) which has a melting point at least 2C below that of substance A and preferably within the range 37-150C (more preferably 43-100C), the melt being held at a temperature below the melting point of substance A, and casting the melt into dosage units. Typical of substance A are fats, e.g. paraffin wax, stearic acid, glyceryl monostearate and paraffin/low molecular weight polyethylene mixtures. Substance B may be water-soluble, e.g. a polyethylene glycol, a polypropylene glycol, an ethylene oxide/propylene oxide condensate or a fatsoluble substance e.g. paraffin wax, hydrogenated vegetable oil, fatty acid esters, stearyl alcohol or cetyl alcohol.
Influenza virus infections are common among children, particularly during the winter season. The infections are often mild, but more serious cases can cause a number of complications, including respiratory illnesses and bacterial infections. HIV infected children may have an increased risk for developing influenza-related bacterial complications, and influenza infections among this population may lead to more rapid disease progression. The current standard of care for HIV infected children is vaccination with an inactivated influenza vaccine (IAIV). However, IAIV is limited in its ability to stimulate the immune systems of HIV infected children with advanced disease. FluMist, a cold-adapted live attenuated influenza vaccine, is both immunogenic and effective in HIV infected children; unfortunately, FluMist is associated with viral shedding, a period of time when the influenza virus used to produce the vaccine may be transmitted to other people. This study will compare the safety and immunogenicity of IAIV and FluMist in HIV infected children and adolescents. This study will also determine the prevalence and duration of FluMist viral shedding in HIV infected children and adolescents who have received the vaccination.

Participants in this study will be randomly assigned to one of two arms. Arm A participants will receive FluMist; Arm B participants will receive IAIV. A single immunization will occur on Day 0 of the study. Arm A participants will have study visits on Days 3, 14, and 28 or home visits on Days 3 and 14. Participants in Arm B will have a study visit on Day 28. A physical exam will be performed at the initial study visit; blood will be collected at study start and at each visit thereafter. Phone calls will be made to participants throughout the study. All participants will have a final study visit after 6 months.
The role of vitamin D deficiency on increased risk for falls and physical dysfunction is unclear. It is also unclear if taking vitamin D improves physical function and reduces fall risk in older adults. This study will look at the potential effects of taking vitamin D regularly on falls and physical function in older adults. A total of 50 individuals with low vitamin D levels (i.e., serum 25-hydroxy Vitamin D range 10 ng/mL to 30 ng/mL) and a recent fall history will be enrolled into a six-month study. During the 6 months in this study, participants will receive capsules containing 800 IU vitamin D, in non-childproof bottles, for two 3-month periods. Participants will be asked to consume one capsule per day for the duration of this six-month study, as well as attend four study visits: Screening Visit, Baseline Visit, 3-Month Visit (in approximately 3 months from the baseline visit), and 6-Month Visit (in approximately 6 months from the baseline visit). During the screening visit, participants will fill out questionnaires, complete the mini-mental status exam, have their blood pressure and pulse taken, and a small sample of blood will be drawn from their vein. During the baseline visit, participants will fill out questionnaires, have their blood pressure, pulse, height, weight, and waist circumference taken, and perform several measures of physical function. Finally, a mouth swab will be performed and a staff member will collect a stool sample that you brought to the study visit. During the 3-Month Visit, participants will complete a questionnaire and have their blood pressure and pulse taken. During the 6-Month Visit, participants will repeat the questionnaires and measures that they performed during the Baseline Visit. The investigators hypothesize that the participants will experience fewer falls and function better physically after taking vitamin D for six months.
Methods, systems, and software are provided for determining copy number variation status of a subject. A first plurality of nucleic acid sequences generated by whole genome sequencing at an average depth of 0.5× to 5× is obtained from a first sample. A second plurality of nucleic acid sequences generated by panel-targeted sequencing is obtained from a second sample. A first mapped dataset is obtained by mapping the first plurality of sequences to positions within a reference genome for the species of the subject. A second mapped dataset is obtained by mapping the second plurality of sequences to positions within a reference construct for genomic regions targeted by the panel-targeted sequencing. A model is applied to all or a portion of the first mapped dataset and all or a portion of the second mapped dataset, or dimensionality reduction components thereof.
At baseline, health care proxies in the intervention arm will be shown a 12-minute Advance Care planning video that describes 3 levels of treatment in advanced dementia: comfort basic and intensive. After viewing the video, the proxies will be asked their preferred level of care for the resident and this choice will be communicated to the residents primary care team in a written form.
The study was designed to investigate the correlation between perioperative adverse cardiovascular events and the degeneration of sensory nerves in patient diagnosed with type 2 diabetes mellitus, undergoing elective non-cardiac surgery. Diabetes mellitus and peripheral sensory nerve degeneration will be diagnosed via clinical evaluation. Serum levels of constituent neuropeptides, including neuropeptide Y (NPY), calcitonin and substance P (SP) and calcitonin gene related peptide (CGRP), and transient receptor potential vanilloid 1 (TRPV1), a molecular nociceptor in peripheral sensory nerves will be quantitatively evaluated. The clinical and the biochemical consequence will be compared between the cohorts of diabetic and non-diabetic patients. The differences and the correlations will be analyzed. The results of the study may reveal whether or not the perioperative adverse cardiovascular events in diabetic patients are correlated with degeneration of peripheral sensory nerves and the alterations in the neuropeptides and TRPV1 are potentially applicable for evaluation of the risk of cardiovascular events in perioperative period in diabetic patients.
BACKGROUND: Evidence shows that low to moderate alcohol consumers seem to live longer than abstainers. Insufficient consideration of subgroups among abstainers and of further behavior-related risk factors for death might be reasons. The aim of this study was to compare alcohol lifetime abstainers, former drinkers, and current consumers with regard to mortality considering tobacco smoking, body overweight, and physical inactivity.
METHODS: A general adult population sample of residents aged 18 to 64 had been drawn at random in northern Germany. Among eligible persons, 4093 (70.2%) participated. Assessments included alcohol consumption by the Alcohol Use Disorders Identification Test Consumption in addition to lifetime alcohol abstinence and former drinking. A score of behavior-related risk factors was built from tobacco smoking, body overweight, and physical inactivity. Twenty years later, a mortality follow-up was conducted. Data of 4028 study participants were analyzed.
RESULTS: At baseline, former alcohol consumers but not current low to moderate alcohol drinkers had more behavior-related risk factors than lifetime abstainers. At follow-up, former alcohol drinkers with two or more behavior-related risk factors had a shorter time to death than lifetime abstainers with 0 or one behavior-related risk factor (hazard ratio 3.43, 95% confidence interval: 1.63-7.20). Low to moderate alcohol drinkers did not survive longer than lifetime alcohol abstainers with 0 or one behavior-related risk factor.
CONCLUSION: The results provide evidence against the assumption that alcohol consumption has a beneficial effect on health and longevity.
<P>PROBLEM TO BE SOLVED: To provide an antiseptic stefilizer which can exclude or reduce the dose of antiseptic microbicides used so far, e.g. paraben, and benzoic acid, and have an excellent antimicrobial potency; and a highly safe composition for application to a human body which contains non or a small amount of a conventional antiseptic microbicide.  <P>SOLUTION: The antiseptic sterilizer contains a 4-10C 1,2-alkanediol and a photosensitizer 201. In the antiseptic sterilizer, the 1,2-alkanediol is one or more of 1,2-pentanediol, 1,2-hexanediol, and 1,2-octanediol. The composition for application to a human body comprises any one of the antiseptic sterilizers.  <P>COPYRIGHT: (C)2008,JPO&INPIT
INTRODUCTION: Cholelithiasis is one of the most common diseases encountered in gastroenterology. Laparoscopic cholecystectomy can be labelled as difficult if the surgery continues for more than 60 minutes or if the cystic artery is injured before ligation or clipping. Predicting difficult laparoscopic cholecystectomy can help the surgeon to be prepared for intraoperative challenges such as adhesions in triangle of Calot, injury to cystic artery or gall stone spillage; and improve patient counseling.
METHODS: In this cross-sectional study, we evaluated 269 patients with diagnosed cholelithiasis and planned for laparoscopic cholecystectomy in the general surgery department of Civil Hospital Karachi. After approval of the institution review board of the Civil Hospital, the data of all the patients was collected along with informed consent. The patients were selected via nonprobability, consecutive sampling.
RESULTS: The prevalence of difficult LC during procedure was 14.5% (39/269). Contingency table showed the true positive, negative and false positive and negative observation and using these observation to compute accuracy. Sensitivity, specificity, PPV, NPV and accuracy of serum c-reactive protein (CRP) in predicting the difficult laparoscopic cholecystectomy in patients of cholelithiasis was 87.2%, 97%, 82.9%, 97.8% and 95.5% respectively. Effect modifiers like age, gender and BMI were controlled by stratification analysis and observed that diagnostic accuracy was above 90% in all stratified groups as presented in the following tables. 175 (65.06%) of 279 patients were females indicating female predominance. In general, 41 patients (15.05%) had CRP serum levels greater than 11 mg/dL out of which 34 patients had to undergo difficult laparoscopic cholecystectomy (DLC), while 223 out of 228 patients with serum CRP levels of less than 11 mg/dL did not face any difficulty during their cholecystectomy. Similar results have been acquired across all age groups and both genders.
CONCLUSION: C Reactive Protein is a potent predictor of difficult laparoscopic cholecystectomy and its conversion preoperatively. Patients with preoperatively high C Reactive Protein CRP levels in serum have more chances of complication intraoperatively and increased chances of conversion from laparoscopic to open surgery. Preoperative C Reactive Protein (CRP) with values >11 mg/dL was associated with the highest odds of presenting difficult laparoscopic cholecystectomy (DLC) in our study. This value possesses good sensitivity, specificity, PPV, and NPV for predicting DLC in our population.